The trial in a much anticipated shareholder class action against engineering firm WorleyParsons scheduled to commence this week has hit a roadblock, with a last minute change in the judge that will hear the matter.
An appeals court has overturned a ruling awarding $2 million in compensation to United Petroleum after the state government compulsorily acquired land on which the petrol retailer operated a service station and restaurant.
Mylan has renewed calls for a temporary injunction against Sun Pharma pending an appeal of a ruling invalidating its patents for Lipidil, and has sued a second generic drug maker, Cipla, over the cholesterol-lowering medication.
The former chief of staff to ex-NAB boss Andrew Thorburn has been arrested and charged for her alleged role in a $40 million fraud against the bank.
AFT Pharmaceuticals has agreed to a court order temporarily restraining it from distributing point of sale material containing updated claims that its painkiller Maxigesic is more effective than other over-the-counter medications.
The ACCC’s chairman Rod Sims has fired a warning shot across the bows of Australia’s gas suppliers, saying high prices had put businesses at risk and urging them to do more to rectify the situation themselves.
Leading defamation barrister Bruce McClintock, SC, has stepped down from representing cricketer Chris Gayle as an appeal by three media organisations against a $326,000 payout gets locked in for a June hearing.
The Australian Building and Construction Commission has been served another costs order after losing a case it brought against a pair of CFMMEU officials who visited a construction site at Melbourne Airport to have a cup of tea with a worker.
Westpac has followed ASIC’s lead, launching a separate appeal to a ruling that it provided financial advice but not personal advice as part of a campaign encouraging customers to roll over external superannuation accounts.
German pharmaceutical company Boehringer has struck back at a patent lawsuit brought by Teva, filing a cross-claim alleging Teva is threatening to infringe three of its patents related to its blockbuster inhaler Spiriva with the planned launch of a competing inhaler in Australia.